The goal of this type of clinical trial study is to evaluate the safety and efficacy of metabolic remodeling nature killer cells as neoadjuvant therapy in newly diagnosed patients with advanced ovarian cancer
Age: 18-70 years old (≥18, ≤70);
Open surgery, laparoscopic surgery, or coarse needle biopsy for histopathological confirmation of advanced (FIGO IIIC/IV stage) high-grade serous ovarian cancer, high-grade endometrioid carcinoma, primary peritoneal carcinoma, and/or fallopian tube carcinoma, etc.;
ECOG score: 0-1;
Blood and tissue specimens before, during, and after treatment can be obtained, and subjects agree to submit blood and tissue specimens to the central laboratory for the purpose of expanding research in this trial;
Patients who have received drugs or other cell immunotherapy in other clinical trials within 28 days before the screening period;
Patients who have had other malignant tumors in the past 5 years;
Acute illnesses are ongoing, or severe illnesses have occurred in the past 2 years, such as patients with active infections or fever, cardiovascular diseases (Grade III or IV heart failure), mental health issues (such as alcoholism, drug abuse);
History of immunodeficiency, including HIV-positive status or other acquired, congenital immunodeficiency diseases;
Anhui Provincial Cancer Hospital
Lead sponsor
Anhui Kecheng intelligent health technology Co., LTD
Collaborator